The P144 peptide inhibitor, developed by ISDIN, targets TGF-β1, a key mediator in fibrotic diseases, particularly systemic sclerosis. Given the lack of approved treatments for skin fibrosis associated with systemic sclerosis in both the EU and the US, P144 presents a significant market opportunity. The trial's focus on topical administration suggests a potential for a novel therapeutic approach in dermatology. The competitive landscape includes existing antifibrotic therapies, but P144's mechanism of action may provide a differentiated profile. Diligence should focus on the safety and tolerability data from the trial, as well as the regulatory pathway for approval.